Dopamine Signaling Leads to Loss of Polycomb Repression and Aberrant Gene Activation in Experimental Parkinsonism

PLoS Genetics

Volumn 10, Issue 9, 2014, Pages

  Södersten, Erik ^a,b   Feyder, Michael ^b   Lerdrup, Mads ^a   Gomes, Ana Luisa ^a   Kryh, Hanna ^a   Spigolon, Giada ^b   Caboche, Jocelyne ^c   Fisone, Gilberto ^b   Hansen, Klaus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; DOPAMINE; DOPAMINE 1 RECEPTOR; HISTONE H3; KRUPPEL LIKE FACTOR 4; LEVODOPA; LYSINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE 1; POLYCOMB GROUP PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; HISTONE; MITOGEN AND STRESS-ACTIVATED PROTEIN KINASE 1; PHOSPHOPROTEIN DARPP 32; PROTEIN BINDING; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATF3 GENE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL PARKINSONISM; GENE ACTIVATION; GENE INDUCTION; GENE REPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENOME ANALYSIS; HOXA2 GENE; IN VIVO STUDY; KLF4 GENE; MOUSE; MOUSE MODEL; MSK1 GENE; MSK2 GENE; NERVE CELL DIFFERENTIATION; NONHUMAN; NPAS4 GENE; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATOR GENE; RNA SEQUENCE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENE LOCUS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PARKINSONISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; GENE EXPRESSION REGULATION; GENETIC LOCI; HISTONES; LEVODOPA; MICE; MICE, KNOCKOUT; PARKINSONIAN DISORDERS; PHOSPHORYLATION; POLYCOMB-GROUP PROTEINS; PROTEIN BINDING; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84907584810     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004574     Document Type: Article

References (60)

1. Kouzarides T, (2007) Chromatin modifications and their function. Cell 128: 693–705.
2. Maze I, Noh KM, Allis CD, (2013) Histone regulation in the CNS: basic principles of epigenetic plasticity. Neuropsychopharmacology 38: 3–22.
3. Di Croce L, Helin K, (2013) Transcriptional regulation by Polycomb group proteins. Nature structural & molecular biology 20: 1147–1155.
4. Margueron R, Reinberg D, (2011) The Polycomb complex PRC2 and its mark in life. Nature 469: 343–349.
5. Simon JA, Kingston RE, (2013) Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol Cell 49: 808–824.
6. Bracken AP, Helin K, (2009) Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nature Reviews Cancer 9: 773–784.
7. Mills AA, (2010) Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nature Reviews Cancer 10: 669–682.
8. Birkmayer W, Hornykiewicz O, (1998) The effect of l-3,4-dihydroxyphenylalanine ( = DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord 4: 59–60.
9. Obeso JA, Olanow CW, Nutt JG, (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23: S2–7.
10. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57: 17–26.
11. Feyder M, Bonito-Oliva A, Fisone G, (2011) L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 5: 71.
12. Darmopil S, Martin AB, De Diego IR, Ares S, Moratalla R, (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66: 603–613.
13. Lebel M, Chagniel L, Bureau G, Cyr M, (2010) Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 38: 59–67.
14. Santini E, Feyder M, Gangarossa G, Bateup HS, Greengard P, et al. (2012) Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism. J Biol Chem 287: 27806–27812.
15. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, et al. (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27: 6995–7005.
16. Brami-Cherrier K, Roze E, Girault JA, Betuing S, Caboche J, (2009) Role of the ERK/MSK1 signalling pathway in chromatin remodelling and brain responses to drugs of abuse. J Neurochem 108: 1323–1335.
17. Maze I, Nestler EJ, (2011) The epigenetic landscape of addiction. Ann N Y Acad Sci 1216: 99–113.
18. Gehani SS, Agrawal-Singh S, Dietrich N, Christophersen NS, et al. (2010) Polycomb group protein displacement and gene activation through MSK-dependent H3K27me3S28 phosphorylation. Mol Cell 39: 886–900.
19. Pavon N, Martin AB, Mendialdua A, Moratalla R, (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59: 64–74.
20. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA, (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62: 800–810.
21. Santini E, Alcacer C, Cacciatore S, Heiman M, Herve D, et al. (2009) L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108: 621–633.
22. Gerfen CR, (2003) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease. Neuroscientist 9: 455–462.
23. Albin RL, Young AB, Penney JB, (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366–375.
24. Bateup HS, Santini E, Shen W, Birnbaum S, Valjent E, et al. (2010) Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 107: 14845–14850.
25. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, et al. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429–1432.
26. Kravitz AV, Freeze BS, Parker PR, Kay K, Thwin MT, et al. (2010) Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466: 622–626.
27. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, et al. (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425: 917–925.
28. Greengard P, (2001) The neurobiology of slow synaptic transmission. Science 294: 1024–1030.
29. Hemmings HC, JrGreengard P, Tung HY, Cohen P, (1984) DARRP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310: 503–505.
30. Nishi A, Snyder GL, Nairn AC, Greengard P, (1999) Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons. J Neurochem 72: 2015–2021.
31. Andersson M, Hilbertson A, Cenci MA, (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6: 461–474.
32. Green TA, Alibhai IN, Unterberg S, Neve RL, Ghose S, et al. (2008) Induction of activating transcription factors (ATFs) ATF2, ATF3, and ATF4 in the nucleus accumbens and their regulation of emotional behavior. J Neurosci 28: 2025–2032.
33. Ramamoorthi K, Fropf R, Belfort GM, Fitzmaurice HL, McKinney RM, et al. (2011) Npas4 regulates a transcriptional program in CA3 required for contextual memory formation. Science 334: 1669–1675.
34. Carta AR, Tronci E, Pinna A, Morelli M, (2005) Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Eur J Neurosci 21: 1196–1204.
35. Sgambato-Faure V, Buggia V, Gilbert F, Levesque D, Benabid AL, et al. (2005) Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol 64: 936–947.
36. Ding Y, Won L, Britt JP, Lim SA, McGehee DS, et al. (2011) Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci U S A 108: 840–845.
37. Santini E, Sgambato-Faure V, Li Q, Savasta M, Dovero S, Fisone G, et al. (2010) Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One 5: e12322.
38. Perlmann T, Wallen-Mackenzie A, (2004) Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells. Cell Tissue Res 318: 45–52.
39. Heiman M, Heilbut A, Francardo V, Kulicke R, Fenster RJ, et al. (2014) Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci U S A 111: 4578–4583.
40. Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, Caryl SE, et al. (2014) Ectopic Nurr1 in striatal neurons results in enhanced levodopa-induced dyskinesias in the 6-OHDA rat model of Parkinson's disease [abstract]. Mov Dis 29 Suppl 1: 61.
41. Bourhis E, Maheux J, Rouillard C, Levesque D, (2008) Extracellular signal-regulated kinases (ERK) and protein kinase C (PKC) activities are involved in the modulation of Nur77 and Nor-1 expression by dopaminergic drugs. J Neurochem 106: 875–888.
42. Cantuti-Castelvetri I, Hernandez LF, Keller-McGandy CE, Kett LR, Landy A, et al. (2010) Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats. PLoS One 5: e13861.
43. Cannizzaro C, Tel BC, Rose S, Zeng BY, Jenner P, (2003) Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Brain Res Mol Brain Res 110: 169–176.
44. Smith Y, Parent A, (1986) Neuropeptide Y-immunoreactive neurons in the striatum of cat and monkey: morphological characteristics, intrinsic organization and co-localization with somatostatin. Brain Res 372: 241–252.
45. Decressac M, Pain S, Chabeauti PY, Frangeul L, Thiriet N, et al. (2012) Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol Aging 33: 2125–2137.
46. Picciotto MR, (2008) Galanin and addiction. Cell Mol Life Sci 65: 1872–1879.
47. Hawes JJ, Picciotto MR, (2004) Characterization of GalR1, GalR2, and GalR3 immunoreactivity in catecholaminergic nuclei of the mouse brain. J Comp Neurol 479: 410–423.
48. O'Donnell D, Ahmad S, Wahlestedt C, Walker P, (1999) Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: distinct distribution from GALR1. J Comp Neurol 409: 469–481.
49. Tsuda K, Tsuda S, Nishio I, Masuyama Y, Goldstein M, (1998) Effects of galanin on dopamine release in the central nervous system of normotensive and spontaneously hypertensive rats. Am J Hypertens 11: 1475–1479.
50. Ericson E, Ahlenius S, (1999) Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission. Brain Res 822: 200–209.
51. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, et al. (2003) Diverse psychotomimetics act through a common signaling pathway. Science 302: 1412–1415.
52. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, et al. (2002) MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22: 2871–2881.
53. Franklin KBJ, Paxinos G (1997) The Mouse Brain in Stereotaxic Coordinates (San Diego: Academic Press).
54. Dahl JA, Collas P, (2008) A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc 3: 1032–1045.
55. Langmead B, Trapnell C, Pop M, Salzberg SL, (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome biology 10: R25.
56. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome research 12: 996–1006.
57. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Royal Stat Soc B 57: 289–300.
58. Anders S, Huber W, (2010) Differential expression analysis for sequence count data. Genome biology 11: R106.
59. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.
60. Dennis G, JrSherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome biology 4: P3.